1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,711 | 0,747 | 12:05 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.08. | Earnings Call: Nanoform reduziert Cash-Burn in Q2 2026 und erzielt regulatorische Fortschritte | 1 | Investing.com Deutsch | ||
| 20.08. | Nanoform Q2 2026 slides: cash burn drops 57% as GMP projects rise | 1 | Investing.com | ||
| 20.08. | Nanoform Finland Oyj Q2 Loss Declines | 2 | RTTNews | ||
| 20.08. | Nanoform steigert Umsatz um 16 % und verringert Quartalsverlust | 2 | Investing.com Deutsch | ||
| 20.08. | Nanoform Finland Oyj: Nanoform Q2 2026 - Positive feedback from scientific advice meeting in the UK, significantly improved cash flow and discussions with CDMOs on sterile GMP for our Biologics technology initiated | 566 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | August 20, 2026 at 08:10:00 EEST
Nanoenzalutamide project continues with the communicated multitrack strategy supported by all partners. After a positive scientific... ► Artikel lesen | |
| 05.08. | Nanoform Finland Oyj: Inside information: Positive Feedback from UK MHRA Scientific Advice Meeting regarding Nanoenzalutamide | 456 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | August 05, 2026 at 12:00:00 EEST
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, announced today that it... ► Artikel lesen | |
| 19.05. | Nanoform Finland Oyj: Nanoform Q1 2026 report - Record first quarter revenue, income and gross margin, first exclusivity deal signed around our Biologics technology | 976 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | May 19, 2026 at 08:10:00 EEST
Record first quarter revenue, income and gross margin. Revenue grew by 45%, gross margin reached 94% and operating costs fell by... ► Artikel lesen | |
| 12.05. | Nanoform Finland Oyj: Inside information: Nanoform Signs First Exclusivity Agreement for Ultra-High Concentration Subcutaneous Delivery | 853 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | May 12, 2026 at 08:00:00 EEST
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it has... ► Artikel lesen | |
| NANOFORM FINLAND Aktie jetzt für 0€ handeln | |||||
| 21.04. | Nanoform Finland Oyj: Resolutions of Nanoform Finland Plc's Annual General Meeting on April 21, 2026 | 674 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | April 21, 2026 at 12:20:00 EEST
Nanoform Finland Plc (the "Company" or "Nanoform") held its Annual General Meeting for 2026 on April 21, 2026 at the Company's... ► Artikel lesen | |
| 02.03. | Nanoform Finland Oyj: The Board of Directors of Nanoform Finland Plc decided on issue of stock options under an option program open to all employees | 1.015 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | March 02, 2026 at 08:10:00 EET
Helsinki, Finland - The Annual General Meeting of Nanoform Finland Plc ("Nanoform") has on 15 April 2025 authorized the company's... ► Artikel lesen | |
| 26.02. | Nanoform Finland Oyj: Nanoform Q4 & FY2025 report - Next: the submission of a marketing authorization application for Nanoenzalutamide in Europe | 947 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | February 26, 2026 at 08:10:00 EET
Product kernel strategy continues to gain traction. Nanoenzalutamide: pivotal human fed and fasted study concluded, three more... ► Artikel lesen | |
| 07.01. | Nanoform Finland Oyj: Inside information: Nanoform starts change negotiations as part of announced new midterm business targets for 2030 | 944 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | January 07, 2026 at 08:05:00 EET
Helsinki, Finland - Nanoform Finland Plc ("Nanoform") starts change negotiations in accordance with the Act on Cooperation.... ► Artikel lesen | |
| 16.12.25 | Nanoform Finland Oyj: Inside information: Nanoform announces new midterm business targets for 2030 | 1.781 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | December 16, 2025 at 07:00:00 EET
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced new midterm... ► Artikel lesen | |
| 12.11.25 | Nanoform Finland Oyj: Nanoform Q3 report: Momentum in kernels continues, commercial cGMP manufacturing license received, first near-term target for 2026 set | 1.995 | GlobeNewswire (Europe) | Nanoform Finland Plc | Company Release | November 12, 2025 at 08:10:00 EET
Our product kernels see good momentum. Nanoenzalutamide progresses with the fed arm of the pivotal human study. Licensing and... ► Artikel lesen | |
| 11.11.25 | Nanoform Finland Oyj: Inside information made public: Nanoform Granted European Commercial cGMP Manufacturing License | 1.157 | GlobeNewswire (Europe) | Nanoform Finland Plc | Inside Information | November 11, 2025 at 08:00:00 EET
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that... ► Artikel lesen | |
| 27.10.25 | Nanoform Finland Oyj: Nanoform Partners With Revio Therapeutics To Develop Long-Acting Locally-Delivered Hydrogel Nanoformulation To Treat Glioma | 1.141 | GlobeNewswire (Europe) | Nanoform Finland Plc | Press Release | October 27, 2025 at 09:10:00 EET
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced a partnership... ► Artikel lesen | |
| 14.10.25 | Nanoform Finland Oyj: Nanoform Outlicenses Nanoencorafenib And Signs Development And Commercialisation Agreement With A.forall And IMGA | 1.126 | GlobeNewswire (Europe) | Nanoform Finland Plc | Press Release | October 14, 2025 at 09:30:00 EEST
Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it has... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 21,750 | +13,76 % | EQS-News: Formycon AG: Formycon optimiert Biosimilar-Entwicklung mit KI-gestützten Technologien: Digitale Lösungen steigern die Entwicklungseffizienz im Rahmen der FYB4GROWTH-Strategie | EQS-News: Formycon AG
/ Schlagwort(e): Kooperation
Formycon optimiert Biosimilar-Entwicklung mit KI-gestützten Technologien: Digitale Lösungen steigern die Entwicklungseffizienz... ► Artikel lesen | |
| ONTO INNOVATION | 243,60 | -0,61 % | SK Hynix zeichnet Onto Innovation für Technologie zur HBM-Fehlererkennung aus | ||
| SOLESENCE | 1,020 | +2,00 % | Solésence, Inc.: Solésence Reports Second Quarter 2026 Financial Results | Quarterly Report Filed on Form 10-Q Company to Host Conference Call at 5:00 p.m. ET Today ROMEOVILLE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically... ► Artikel lesen | |
| VEECO INSTRUMENTS | 46,340 | +4,89 % | Why Veeco Instruments Stock Crushed it Last Month | ||
| NANOVEU | 0,035 | -2,78 % | Nanoveu (ASX:NVU) 33 Customer Opportunities Put First Chip Revenue in Sight | ||
| GOMSPACE | 0,886 | +0,28 % | GomSpace A/S: GomSpace Launches GOMX-5 to Demonstrate Next-Generation Satellite Communications Technologies | The ESA-supported mission validates next-generation communications technologies in orbit, strengthens GomSpace's flight heritage, and supports future commercial... ► Artikel lesen | |
| ZENTEK | 0,408 | 0,00 % | Zentek Ltd: Zentek appoints Lomets as commercialization VP | ||
| OBDUCAT | 0,027 | -3,57 % | NGM MARKET NOTICE: #26-72 Decision by the Disciplinary Committee regarding Obducat AB (publ) | ||
| GAUZY | 4,750 | +5,32 % | GAUZY LTD: Gauzy Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal | TEL AVIV, Israel, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Gauzy Ltd. (Nasdaq: GAUZ) ("Gauzy" or the "Company"), a global leader in vision and light control technologies, today announced receipt of a delisting... ► Artikel lesen | |
| NVE | 99,00 | 0,00 % | Dividendenbekanntmachungen (03.08.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AMERISERV FINANCIAL INC US03074A1025 0,03 USD 0,026 EUR BF SPA IT0005187460 - 0,038 EUR CITIZENS & NORTHERN CORPORATION US1729221069 0... ► Artikel lesen | |
| KOPIN | 3,888 | +4,85 % | Stifel bestätigt Kaufempfehlung für Kopin nach neuem Rüstungsauftrag | ||
| ACACIA RESEARCH | 3,800 | +0,53 % | ACACIA RESEARCH CORP - 10-Q, Quarterly Report | ||
| ADVANCE ZINCTEK | 0,320 | 0,00 % | ADVANCE ZINCTEK LIMITED: First Quarter FY27 Australian Revenue Down 71% | ||
| LAMPETIA | 0,135 | -8,16 % | EQS-Adhoc: Lampetia AG: Einigung über die Beendigung von Rechtsstreitigkeiten | EQS-Ad-hoc: Lampetia AG / Schlagwort(e): Sonstiges
Lampetia AG: Einigung über die Beendigung von Rechtsstreitigkeiten
16.07.2026 / 22:00 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
| RIBER | 8,040 | 0,00 % | Riber Reports Improved Results For The First Half Of 2026 | RIBER REPORTS IMPROVED RESULTS FOR THE FIRST HALF OF 2026 Revenues of €12.7m (+19%) and gross margin of €5.1m (+31%), representing 39.8% of revenuesPositive net income of €0.2m, compared with -€0.8m... ► Artikel lesen |
Das Unternehmen NANOFORM FINLAND OYJ kann der Branche Nanotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,003 (-0,40 %) liegt der Kurs bei 0,750 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOFORM FINLAND OYJ finden Sie auf Wallstreet Online.